MZE829 for APOL1 kidney disease
Part of Kidney & urinary clinical trials.
This trial tests an experimental drug called MZE829 for people with kidney disease linked to the APOL1 gene. It aims to see if the drug can help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have two copies of the high-risk APOL1 gene variants (G1/G1, G2/G2, or G1/G2).
- You must have chronic kidney disease with persistent protein in your urine (albuminuria).
- You cannot have had an organ or bone marrow transplant.
- You must not have had active cancer in the past 2 years, except for certain early-stage or treated cancers.
- You cannot have Type 1 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether VX-147 can improve kidney disease caused by an APOL1 gene change, which often leads to protein leaking into the urine. It includes both adults and children and focuses on safety and effectiveness over time.
This trial tests an experimental drug (AZD2373) for people with kidney disease caused by APOL1 gene changes. It aims to find the safest and most effective dose to slow kidney damage.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
This study tests an investigational drug that blocks a protein called ANGPTL3, which may help protect the kidneys in people with type 2 diabetes and diabetic kidney disease. It aims to see if the drug can reduce kidney damage and improve overall health.
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
Hear when a new Proteinuric Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.